Rabbit Polyclonal BCAT2 antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 9 publications. Immunogen corresponding to Recombinant Fragment Protein within Human BCAT2 aa 1-350.
pH: 7
Preservative: 0.025% Proclin 300
Constituents: 78% PBS, 20% Glycerol (glycerin, glycerine), 1% BSA
WB | IHC-P | |
---|---|---|
Human | Tested | Tested |
Mouse | Predicted | Predicted |
Rat | Predicted | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/500 - 1/3000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 - 1/500 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Select an associated product type
Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine (PubMed:17050531, PubMed:25653144, PubMed:8702755). May also function as a transporter of branched chain alpha-keto acids (By similarity).
BCATM, BCT2, ECA40, BCAT2, BCAT(m), Placental protein 18, PP18
Rabbit Polyclonal BCAT2 antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 9 publications. Immunogen corresponding to Recombinant Fragment Protein within Human BCAT2 aa 1-350.
pH: 7
Preservative: 0.025% Proclin 300
Constituents: 78% PBS, 20% Glycerol (glycerin, glycerine), 1% BSA
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Paraffin embedded Ca922 tissue stained for BCAT2 using ab95976 at 1/100 dilution in immunohistochemical analysis.
Paraffin embedded Ca922 tissue stained for BCAT2 using ab95976 at 1/500 dilution in immunohistochemical analysis.
Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.
All lanes: Western blot - Anti-BCAT2 antibody (ab95976) at 1/1000 dilution
Lane 1: Non-transfected (–) 293T whole cell extracts at 30 µg
Lane 2: Transfected (+) 293T whole cell extracts at 30 µg
All lanes: HRP-conjugated anti-rabbit IgG antibody
Observed band size: 44 kDa
BCAT2 was immunoprecipitated from 0.35 mg MCF7 (human breast adenocarcinoma epithelial cell) whole cell lysate with Anti-BCAT2 antibody [EPR27488-72] ab307833 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using Anti-BCAT2 antibody [EPR27488-72] ab307833 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.
Lane 1: MCF7 whole cell lysate 10 ug
Lane 2: Anti-BCAT2 antibody [EPR27488-72] ab307833 IP in MCF7 whole cell lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of Anti-BCAT2 antibody [EPR27488-72] ab307833 in MCF7 whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: Lanes 1-3: 6 seconds (left), Lanes 1-3: 180 seconds (right).
The IP experiment was performed by Anti-BCAT2 antibody [EPR27488-72] ab307833 using MCF cells. On the left the IP blot was probed with Anti-BCAT2 antibody [EPR27488-72] ab307833 and on the right the blot was probed by another anti-BCAT2 antibody (ab95976)(1:1000 dilution).
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com